Overview

Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) D2 receptors, brain structure, brain function, and information processing to each other and to psychopathology. Additionally, the investigators want to examine the influence of D2 receptor blockade on these disturbances. The investigators expect disturbances in the dopaminergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and investigators expect D2 receptor blockade to reverse some of the functional and cognitive impairments. The investigators do not expect any effect of treatment on brain structure.
Phase:
N/A
Details
Lead Sponsor:
Birte Glenthoj
Collaborators:
Copenhagen Hospital Corporation
Glostrup University Hospital, Copenhagen
Institute of Psychiatry, London
Rigshospitalet, Denmark
UMC Utrecht
Treatments:
Amisulpride
Sulpiride
Sultopride